Karyopharm Therapeutics Inc

NASDAQ:KPTI   3:59:51 PM EDT
7.74
+0.28 (+3.75%)
Products

Karyopharm And Menarini Group Enter Into Exclusive License Agreement To Commercialize Nexpovio (Selinexor) In Europe And Other Key Global Territories

Published: 12/21/2021 14:07 GMT
Karyopharm Therapeutics Inc (KPTI) - Karyopharm and Menarini Group Enter Into Exclusive License Agreement to Commercialize Nexpovio® (selinexor) in Europe and Other Key Global Territories.
Karyopharm - to Receive $75 Million Upfront, Then Eligible to Receive Up to $202.5 Million in Future Milestones, Plus Tiered, Double-digit Royalties on Sales.
Karyopharm Therapeutics Inc - Review by Chmp for Nexpovio Maa Expected to Be Completed During First Half of 2022.